COVID-19 mRNA Vaccination Reduces Guillain-Barré Syndrome Risk: Evidence from a Large Longitudinal Cohort Study

Area of Science:

• Immunology
• Epidemiology
• Vaccinology

Background:

• Previous studies on COVID-19 vaccination and Guillain-Barré syndrome (GBS) yielded inconsistent results due to data limitations.
• A need existed for robust data to clarify the association between COVID-19 vaccination and GBS risk.

Purpose of the Study:

• To investigate the association between COVID-19 vaccination and GBS risk using a large-scale longitudinal cohort.
• To compare GBS risk among vaccinated, infected, and unvaccinated/uninfected individuals.

Main Methods:

• Utilized the National COVID Cohort Collaborative (N3C) database for a large longitudinal cohort study.
• Employed incidence risk ratios (IRR) and multivariable Cox regression to analyze GBS risk.
• Controlled for factors including sex, vaccine dose, and pre-existing comorbidities.

Main Results:

• COVID-19 infection increased GBS occurrence, while vaccination significantly reduced GBS risk (IRR = 0.39, P < 0.01).
• The protective effect was specific to mRNA vaccines (BNT162b2, mRNA-1273), not adenoviral-vector vaccines.
• Prior vaccination also lowered infection-associated GBS risk. Comorbidities like stroke and autoimmune diseases were linked to GBS.

Conclusions:

• COVID-19 mRNA vaccination is associated with a significantly reduced risk of Guillain-Barré syndrome.
• This study supports the safety profile of mRNA COVID-19 vaccines.
• Further research into the mechanisms behind this protective association is warranted.